Abstract. To evaluate the possibility of using the LRH agonist buserelin as a contraceptive for lactating women we have investigated the passage of buserelin into breast milk and explored possible biological activity in the infant. Eleven mothers received 600 \ g=m\ gbuserelin by nasal spray. Buserelin was measured by radioimmunoassay in the breast milk of these mothers, and values ranged from undetectable levels (less than 15 pg/ml) to 8800 pg/ml. The maximum amount of buserelin that an infant could ingest during an average feed would be 1\p=n-\2\g=m\g.In adult men ingestion of 600 \ g=m\ g buserelin dissolved in cows milk was without biological effect upon both serum and urinary levels of luteinizing hormone. There was no change in the levels of LH found in the urine of infants fed by women who had received 600 \g=m\g buserelin by nasal spray. We conclude that the small amount of buserelin passing into the breast milk of these volunteers was without biological activity when ingested by the infant. 
The choice of contraceptive methods presently available to lactating mothers is limited. There is a need for a reliable, acceptable and easily admini¬ stered method of contraception which does not interfere with lactation and is non-steroidal. To this end we are currently evaluating the effective¬ ness of luteinizing hormone releasing hormone agonist (LRH agonist) , buserelin, as a contracep¬ tive for lactating women. This report outlines the investigations that have been carried out prior to regular administration of buserelin to breast feeding mothers.
Breast feeding is nutritionaly good for the infant (Buchanan 1975) . The contraceptive effects of breast feeding have been investigated (Howie & McNeilly 1982; Short 1984) , and it has been shown that while full breast feeding is asso¬ ciated with the suppression of ovarian activity in women post-partum when supplementary feeds are given (Howie et al. 1981) In vitro incubation of breast milk samples containing buserelin, as described above, demonstrated significant degradation, but the addition of bacitracin at a concen¬ tration of 10"3 mol largely overcame this degradation (Fig. 2) .
Ten lactating mothers who were expressing and dis¬ carding their breast milk at 5-10 days post-partum (their infants having been temporarily admitted to the Special Care Baby Unit), were recruited from the post¬ natal wards of the Simpson Memorial Maternity Pavi¬ lion, Edinburgh. Six mothers received 600 µg buserelin by nasal spray, and 4 took a placebo spray. Samples of breast milk and urine were collected prior to and at 2, 4, 8 and 24 h after receiving the nasal spray. Bacitracin was added to the breast milk samples to give a final concentration of "3 M to inhibit degradation. All the samples collected were stored at -20°C until assayed. The breast milk and urine samples were assayed for buserelin and its metabolites, and the urine samples were also assayed for creatinine.
After establishing that only a small amount of buse¬ relin and its metabolites passed into the breast milk of the volunteers, and that oral ingestion of large quanti¬ ties of buserelin by the adult males was without biologi¬ cal effect, we proceeded to recruit mothers at 6 weeks post partum, who were breast feeding their infants, to receive the buserelin nasal spray. Fourteen breast feed¬ ing mothers were recruited from the post-natal wards.
At six weeks post partum, 11 of these mothers received a single, 600 µg dose of buserelin by nasal spray.
Three mothers received a placebo spray. The four¬ teen mothers breast fed their infants 2 to 3 h after receiving the nasal spray. 
Radioimmunoassays
Buserelin levels in urine and breast milk were deter¬ mined by double antibody radio-immunoassays using a rabbit antibody (R104) raised against buserelin con¬ jugated to human serum albumin (Fraser et al. 1983) in Edinburgh, and in Frankfurt using antibody 636 (Sandow et al. 1981 (Sandow et al. , 1984 (Sandow et al. , 1985 . (Fig. lb) .
Furthermore, levels of buserelin were signifi¬ cantly (P < 0.0 1 ¿-test) lower in urine after oral administration compared to its application with the nasal spray (Fig. lc) . 
Main study
The levels of buserelin present in breast milk, collected from mothers between 5-10 days post partum, are shown in (Fig. 3) . In one infant's urine a small amount of buserelin immunoactivity was detectable (62 pg/ml urine) in the sample col¬ lected at 6 h after breast feeding from the mother who had 8800 pg/ml in her breast milk, but there was no evidence of a rise in urinary LH. There was no detectable buserelin in any of the other samples collected from these infants.
Discussion
We have demonstrated that only a small amount of buserelin passes into the breast milk of lactating mothers after administration of 600 µg buserelin would be difficult to demonstrate because it is uncertain as to whether the buserelin entering the breast milk is intact or already partially degraded. Buserelin is primarily degraded in the liver and kidneys, the degradation products being excreted in the urine (Sandow et al. 1984 (Sandow et al. , 1985a . The addition of bacitracin to the breast milk samples ensures that further degradation cannot occur in vitro before the samples are assayed.
The rise of the levels of LH seen in the urine of mothers who received 600 µg buserelin by nasal spray at 6 weeks post partum is consistent with other reports of a return of pituitary responsive¬ ness to LRH by the 6th week after delivery (Keye &Jaffe 1976).
In conclusion, we have demonstrated that when buserelin is administered in the puerperium at a dose of 600 µg by nasal spray, it can be detected in breast milk, but that the levels present in the milk have no biological effect on the infant and are significantly lower than the levels known to be needed to exert an effect in adults. We conclude from this study that longer term studies of the use of buserelin as a possible post partum contracep¬ tive are warranted.
